Gillian Woollett Gives Insight Into What the US Can Learn From Europe's Biosimilar Adoption
March 29th 2022Gillian Woollett, MA, Dphil, vice president and head of regulatory strategy and policy at Samsung Bioepis, explains why there's no easy to solution to getting the US biosimilar market to the same level as Europe.
Jeffery Casberg Previews His Presentations at AMCP 2022
March 27th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products coming down the pipeline at the upcoming Academy of Managed Care Pharmacy (AMCP) annual meeting.
Phase 3 Trial Confirms Equivalence Between Tuznue, Reference Trastuzumab in ERBB2+ Breast Cancer
March 23rd 2022An international phase 3 study of patients with erb-B2 receptor tyrosine kinase 2-positive (ERBB2+) breast cancer showed that Tuznue, a trastuzumab biosimilar, had comparable safety and efficacy to the reference product (Herceptin).
China’s NMPA Grants Greater Access to Rheumatology Biosimilars
March 21st 2022Since the start of 2022, China’s National Medicinal Products Administration (NMPA) has made strides to increase access to biosimilar products for various rheumatic conditions, including 3 biosimilar approvals and 1 biosimilar receiving an expanded indication.
Companies Sign Manufacturing Agreements Aimed at Increasing Biosimilar Access, Affordability
March 16th 2022OcyonBio signed a Good Manufacturing Practice (GMP) agreement for the manufacturing of biosimilars in Puerto Rico, while Evio Pharmacy Solutions implemented a strategy aimed at increasing biosimilar affordability.
Celltrion Biosimilar Demonstrates Equivalence With Xolair in Phase 1 Study
March 14th 2022A phase 1 study testing Celltrion Healthcare’s omalizumab biosimilar in healthy subjects showed similar safety and pharmacokinetic profiles to the reference product (Xolair), as presented at the American Academy of Allergy Asthma and Immunology’s annual meeting.
AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023
March 8th 2022AbbVie settles outstanding lawsuits, including its case related to the International Trade Commission (ITC), with Alvotech, giving Alvotech the green light to launch its high-concentration, citrate-free adalimumab biosimilar referencing Humira in July 2023, pending FDA approval.